284 related articles for article (PubMed ID: 25803323)
1. New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma.
Costa V; Esposito R; Ziviello C; Sepe R; Bim LV; Cacciola NA; Decaussin-Petrucci M; Pallante P; Fusco A; Ciccodicola A
Oncotarget; 2015 May; 6(13):11242-51. PubMed ID: 25803323
[TBL] [Abstract][Full Text] [Related]
2.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
3. Genetic landscape of papillary thyroid carcinoma in the Chinese population.
Liang J; Cai W; Feng D; Teng H; Mao F; Jiang Y; Hu S; Li X; Zhang Y; Liu B; Sun ZS
J Pathol; 2018 Feb; 244(2):215-226. PubMed ID: 29144541
[TBL] [Abstract][Full Text] [Related]
4. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
5. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
6. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
[TBL] [Abstract][Full Text] [Related]
8. Identification of Unique, Heterozygous Germline Mutation, STK11 (p.F354L), in a Child with an Encapsulated Follicular Variant of Papillary Thyroid Carcinoma within Six Months of Completing Treatment for Neuroblastoma.
Buryk MA; Picarsic JL; Creary SE; Shaw PH; Simons JP; Deutsch M; Monaco SE; Nikiforov YE; Witchel SF
Pediatr Dev Pathol; 2015; 18(4):318-23. PubMed ID: 25751324
[TBL] [Abstract][Full Text] [Related]
9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
10. Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma.
Lu Z; Zhang Y; Feng D; Sheng J; Yang W; Liu B
Oncotarget; 2017 Jul; 8(28):45784-45792. PubMed ID: 28507274
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
[TBL] [Abstract][Full Text] [Related]
14. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
15. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
16. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.
Cordioli MI; Moraes L; Bastos AU; Besson P; Alves MT; Delcelo R; Monte O; Longui C; Cury AN; Cerutti JM
Thyroid; 2017 Feb; 27(2):182-188. PubMed ID: 27849443
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
18. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
[TBL] [Abstract][Full Text] [Related]
19. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
[TBL] [Abstract][Full Text] [Related]
20. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
